Efficient synthetic inhibitors of anthrax lethal factor.

Inhalation anthrax is a deadly disease for which there is currently no effective treatment. Bacillus anthracis lethal factor (LF) metalloproteinase is an integral component of the tripartite anthrax lethal toxin that is essential for the onset and progression of anthrax. We report here on a fragment-based approach that allowed us to develop inhibitors of LF. The small-molecule inhibitors we have designed, synthesized, and tested are highly potent and selective against LF in both in vitro tests and cell-based assays. These inhibitors do not affect the prototype human metalloproteinases that are structurally similar to LF. Initial in vivo evaluation of postexposure efficacy of our inhibitors combined with antibiotic ciprofloxacin against B. anthracis resulted in significant protection. Our data strongly indicate that the scaffold of inhibitors we have identified is the foundation for the development of novel, safe, and effective emergency therapy of postexposure inhalation anthrax.

[1]  Kurt Wüthrich,et al.  Nmr in drug discovery , 2002, Nature Reviews Drug Discovery.

[2]  Cesare Montecucco,et al.  Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNγ‐induced release of NO and TNFα , 1999 .

[3]  J. Levin.  The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. , 2004, Current topics in medicinal chemistry.

[4]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[5]  B. Sellman,et al.  Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax , 2001, Science.

[6]  R. Powers,et al.  The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. , 2004, Current topics in medicinal chemistry.

[7]  K D Paull,et al.  Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. , 1998, Science.

[8]  M. Mrksich,et al.  Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor , 2004, Nature Biotechnology.

[9]  M. Mock,et al.  Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. , 1998, Biochemical and biophysical research communications.

[10]  Oliver Zerbe.  BioNMR in drug research , 2003 .

[11]  Jadwiga Bienkowska,et al.  Crystal structure of the anthrax lethal factor , 2001, Nature.

[12]  Nicola Mongelli,et al.  A general NMR method for rapid, efficient, and reliable biochemical screening. , 2003, Journal of the American Chemical Society.

[13]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[14]  R. Liddington,et al.  Crystal structure of the anthrax toxin protective antigen , 1997, Nature.

[15]  D. Acosta,et al.  On the role of macrophages in anthrax. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Maurizio Pellecchia,et al.  NMR-based structural characterization of large protein-ligand interactions , 2002, Journal of biomolecular NMR.

[17]  Thomas Peters,et al.  NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. , 2003, Angewandte Chemie.

[18]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[19]  Lewis C Cantley,et al.  The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor , 2004, Nature Structural &Molecular Biology.

[20]  Dawoon Jung,et al.  NMR-based techniques in the hit identification and optimisation processes , 2004, Expert opinion on therapeutic targets.

[21]  Maurizio Pellecchia,et al.  Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules. , 2004, Chemistry & biology.

[22]  Stuart J. Nelson,et al.  The MeSH Translation Maintenance System: Structure, Interface Design, and Implementation , 2004, MedInfo.

[23]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[24]  J W Smith,et al.  Substrate Hydrolysis by Matrix Metalloproteinase-9* , 2001, The Journal of Biological Chemistry.

[25]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[26]  John A. Young,et al.  Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  H. Smith,et al.  Observations on Experimental Anthrax: Demonstration of a Specific Lethal Factor produced in vivo by Bacillus anthracis , 1954, Nature.

[28]  P. Hanna.  Anthrax pathogenesis and host response. , 1998, Current topics in microbiology and immunology.

[29]  John A. Young,et al.  Identification of the cellular receptor for anthrax toxin , 2001, Nature.

[30]  Michael Karin,et al.  Macrophage Apoptosis by Anthrax Lethal Factor Through p38 MAP Kinase Inhibition , 2002, Science.

[31]  W. Jahnke,et al.  Spin label enhanced NMR screening. , 2001, Journal of the American Chemical Society.

[32]  M. Mock,et al.  Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. , 2000, The Biochemical journal.

[33]  S. Leppla,et al.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.